In the tumour microenvironment, where breast cancer cells interact with adipocytes, the fibrous stroma and the immune cells of the inflammatory infiltrate, CCL5 production increases and is sustained [22], thereby ensuring that CCL5 activation of CCR5 will provide a steady supply of glutamine to support the aggressive proliferation of breast cancer cells. The gene discussed is CCL5; the disease is breast cancer.